# Ultragenyx Pharmaceutical Inc. Type: Company (RARE) Source: GetYourBrief — https://getyourbrief.com/entity/ultragenyx-pharmaceutical-inc Canonical HTML page: https://getyourbrief.com/entity/ultragenyx-pharmaceutical-inc ## Timeline - **2026-Q3**: Motion to Dismiss Phase — Defendants expected to file motions to dismiss based on Safe Harbor protections for forward-looking statements. - **2026-Q3**: Discovery Phase Begins — Courts likely to rule on motions to dismiss, leading to the exchange of internal corporate documents. - **2026-Q3**: Lead Counsel Appointment — Expected timeframe for the court to designate the lead plaintiff and legal representation. - **2026-05-11**: Lead Plaintiff Deadline — Final day for affected investors to petition the court to lead the class action. - **2026-04-15**: Lead Plaintiff Deadline — Estimated deadline for investors to file motions to be appointed as lead plaintiff in the respective cases. - **2026-04-15**: Lead Plaintiff Deadline (Est.) — Typical 60-day window for investors to petition the court to lead the consolidated class action. - **2026-04-15**: Lead Plaintiff Deadline (Estimated) — Expected window for investors to file motions to lead the class actions against RARE, MREO, and NAVAN. - **2026-03-12**: Lawsuit Announcements — Schall Law Firm files class action notices for Soleno Therapeutics and Ultragenyx Pharmaceutical. - **2026-03-12**: Litigation Commencement — Schall Law Firm announces class action lawsuits against both SLNO and RARE. - **2026-03-06**: Market Reaction — Investors and analysts begin assessing the potential litigation overhang on RARE, MREO, FRMI, and NAVN. - **2026-03-05**: Investor Alerts Issued — Pomerantz Law Firm releases simultaneous reminders for class action lawsuits against four companies. - **2026-03-05**: Investor Alerts Issued — Pomerantz Law Firm releases multiple reminders for class action deadlines across the biotech sector. - **2026-03-05**: Coordinated Legal Alerts — Pomerantz Law Firm issues a series of reminders for class action deadlines across four major firms. - **2026-02-26**: Soleno Executive Turnover — Official filing confirms the departure of several directors and officers. - **2026-02-25**: Soleno Financial Results — Soleno files annual results and operational updates. ## Recent coverage (6 stories, network-wide) ### Schall Law Firm Targets Soleno and Ultragenyx in Securities Fraud Litigation 2026-03-12 10:06:11 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 The Schall Law Firm has initiated securities fraud class action lawsuits against biotech players Soleno Therapeutics and Ultragenyx Pharmaceutical. The legal actions follow a series of corporate disclosures in early 2026, inviting impacted investors to lead the litigation efforts. Full story: https://getbiobrief.com/story/soleno-ultragenyx-securities-fraud-lawsuits-schall ### Soleno and Ultragenyx Face Securities Fraud Litigation Over Disclosure Risks 2026-03-12 10:05:39 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 The Schall Law Firm has initiated securities fraud class action lawsuits against rare disease biotechs Soleno Therapeutics and Ultragenyx Pharmaceutical. These legal challenges highlight the heightened scrutiny on clinical data transparency and regulatory communications in the high-stakes orphan drug sector. Full story: https://gethealthbrief.com/story/soleno-ultragenyx-securities-fraud-lawsuits-2026 ### Schall Law Firm Targets Soleno and Ultragenyx in Dual Securities Fraud Actions 2026-03-12 10:04:00 · Sector: legal · Sentiment: Neutral · Impact: 5/10 · Sources: 2 The Schall Law Firm has initiated securities fraud class actions against Soleno Therapeutics and Ultragenyx Pharmaceutical, alleging violations of federal securities laws. The firm is currently seeking lead plaintiffs to represent the class in these high-stakes biotech litigations following potential misrepresentations to the market. Full story: https://getlegalbrief.com/story/schall-law-firm-soleno-ultragenyx-securities-fraud ### Pomerantz Law Firm Issues Securities Class Action Deadlines for Four Firms 2026-03-05 23:21:48 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 4 Pomerantz Law Firm has issued urgent reminders for investors regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These legal actions target alleged securities fraud and disclosure failures, setting critical deadlines for lead plaintiff applications. Full story: https://getfinancebrief.com/story/pomerantz-law-firm-securities-litigation-deadlines-2026 ### Pomerantz Law Firm Issues Class Action Deadlines for Major Biotech Firms 2026-03-05 23:21:15 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 4 Pomerantz Law Firm has issued urgent reminders to investors regarding class action deadlines for Ultragenyx, Mereo BioPharma, Navan, and Fermi. These legal actions follow allegations of misleading statements and failures to disclose material risks concerning clinical data and financial projections. Full story: https://getbiobrief.com/story/pomerantz-biotech-class-action-deadlines-2026 ### Pomerantz Law Firm Targets Biotech and Tech Sectors in Securities Class Actions 2026-03-05 23:21:10 · Sector: legal · Sentiment: Neutral · Impact: 5/10 · Sources: 4 Pomerantz Law Firm has issued a series of investor alerts regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These filings highlight a surge in securities litigation targeting volatility in the biotechnology and emerging technology sectors, emphasizing critical lead plaintiff deadlines for affected shareholders. Full story: https://getlegalbrief.com/story/pomerantz-securities-class-actions-biotech-tech-2026 --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.